Infliximab treatment for rheumatic disease: Clinical and radiological efficacy

Annals of the Rheumatic Diseases

Volumn 61, Issue SUPPL. 2, 2002, Pages

  St Clair, E W ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; PLACEBO; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANKYLOSING SPONDYLITIS; ARTHRITIS; BONE RADIOGRAPHY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; HUMANS; RHEUMATIC DISEASES; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036839224     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (20)

1. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993;30:1443-53.
2. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 1993;36:1681-90.
3. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
4. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-7.
5. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
6. Kavanaugh A, StClair EW, McCune WJ, Braakman T, Lipsky P. Chimeric anti-tumor necrosis factor-α monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 2000;27:841-50.
7. Maini R, St.Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor α monaclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. Lancet 1999;354:1932-9.
8. Lipsky PE, van der Heijde DMFM, St.Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
9. Lipsky P, van der Heijde D, St.Clair EW, Smolen J, Furst D, Kalden J, et al. 102-Wk clinical and radiologic results from the ATTRACT trial: A 2 year, randomized, controlled, phase 3 trial of infliximab (Remicade™) in patients with active rheumatoid arthritis despite methotrexate. Arthritis Rheum 2000;43 (suppl):S269.
10. Van der Heijde D. Plain X-rays in rheumatoid arthritis: Overview of scoring methods, their reliability and applicability. Baillieres Clin Rheumatol 1996;10:435-3.
11. St.Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis. Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1451-9.
12. Van den Bosch F, Kruithof E, Baeten D, de Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: An open pilot study. Arthritis Rheum 2000;59:428-33.
13. Kruithof E, Van den Bosch F, Baeten D, Herssens A, de Keyser F, Mielants H, et al. Repeated infusions of infliximab, a chimeric anti-TNFα antibody, in patients with active spondyloarthropathy: One year follow-up. Ann Rheum Dis 2002;61:207-12.
14. Van den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 2002;46:755-65.
15. Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor α monoclonal antibody infliximab. Arthritis Rheum 2000;43:1346-52.
16. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial. Lancet 2002;359:1187-93.
17. Van der Heijde D, Bellamy N, Calin A, Dougados M, Khan MA, van der Linden S. Preliminary core sets for endpoints in ankylosing spondylitis. J Rheumatol 1997;24:2225-9.
18. Oglivie AL, Antoni C, Denchant C, Manger B, Kalden JR, Schuler G, et al. Treatment of psoriatic arthritis with anti-tumor necrosis factor-α antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001;144:587-9.
19. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial. Lancet 2001;357:1842-7.
20. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet 2000;356:385-90.